Stockscreener 앱 받기
7.90
14.00%
0.97
시간 외 거래:
8.10
0.20
+2.53%
전일 마감가:
$6.93
열려 있는:
$7.18
하루 거래량:
4.81M
Relative Volume:
3.98
시가총액:
$408.41M
수익:
$170.44M
순이익/손실:
$-193.88M
주가수익비율:
-2.1044
EPS:
-3.7541
순현금흐름:
$-126.38M
1주 성능:
+28.87%
1개월 성능:
+38.11%
6개월 성능:
-40.02%
1년 성능:
-8.78%
1일 변동 폭
$7.18
$8.73
1주일 범위
$5.88
$8.73
52주 변동 폭
$5.455
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.90 | 365.50M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-07 | 재개 | Raymond James | Outperform |
| 2024-11-15 | 재개 | Morgan Stanley | Overweight |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-06-07 | 개시 | Goldman | Buy |
| 2024-03-11 | 개시 | H.C. Wainwright | Buy |
| 2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 재개 | Raymond James | Outperform |
| 2023-11-01 | 개시 | Stifel | Buy |
| 2023-06-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Wedbush | Neutral |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-14 | 재개 | Raymond James | Outperform |
| 2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
| 2018-11-08 | 재확인 | BofA/Merrill | Neutral |
| 2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
| 2018-05-09 | 재확인 | Barclays | Overweight |
| 2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 개시 | Mizuho | Neutral |
| 2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy - Eastern Progress
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Eastern Progress
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax - Barchart.com
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $26 - Moomoo
H.C. Wainwright lowers Regenxbio stock price target on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright lowers Regenxbio stock price target on trial data - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Climb Bio (CLYM) - The Globe and Mail
Understanding Momentum Shifts in (RGNX) - Stock Traders Daily
JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc. - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
RGNX Maintains Rating by HC Wainwright & Co. -- Price Target Low - GuruFocus
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
RGNX Maintains Rating by HC Wainwright & Co. -- Price Target Lowered to $26 - GuruFocus
Regenxbio slides after late-stage trial data for Duchenne therapy - MSN
JPMorgan affiliates report 4.4% stake in REGENXBIO (RGNX) in 13G/A - Stock Titan
REGENXBIO (RGNX) offers exchange of 2.9M eligible options for replacements - Stock Titan
REGENXBIO (NASDAQ: RGNX) investors back board, reject executive option swap - Stock Titan
REGENXBIO (RGNX) awards director Daniel Tasse RSUs and options - Stock Titan
REGENXBIO (RGNX) director receives new RSU and stock option awards - Stock Titan
[Form 4] REGENXBIO Inc. Insider Trading Activity - Stock Titan
REGENXBIO (RGNX) director Kenneth Mills granted RSUs and 46,600 stock options - Stock Titan
REGENXBIO (RGNX) director awarded 9,807 RSUs and 46,600 stock options - Stock Titan
Director at REGENXBIO (RGNX) receives RSU and option grants - Stock Titan
REGENXBIO Inc. (RGNX) director receives new RSU and stock option grants - Stock Titan
Equity grants to REGENXBIO (NASDAQ: RGNX) director Jean Bennett - Stock Titan
How The REGENXBIO (RGNX) Investment Story Is Evolving Without New Analyst Commentary - Yahoo Finance
RGNX Should I Buy - Intellectia AI
RGNX stock on track for worst day ever as big Q1 loss, cash concerns eclipse Duchenne trial success - MSN
Regenxbio files $300M mixed shelf offering - MSN
REGENXBIO to push for accelerated approval of DMD gene therapy - MSN
Stifel reiterates Buy rating on Regenxbio stock ahead of trial data - Investing.com UK
Stifel reiterates Buy rating on Regenxbio stock ahead of trial data By Investing.com - Investing.com South Africa
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Avoiding Lag: Real-Time Signals in (RGNX) Movement - Stock Traders Daily
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace
Morgan Stanley Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $6.25 - Moomoo
RGNX: Rolling BLA for Duchenne gene therapy set for Q3 2024, with robust data and regulatory momentum - TradingView
Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway - Insider Monkey
RegenXbio’s RGX-202 Pivotal Win Lifts Outlook - TipRanks
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):